Alcon Inc. Q3 2025 Earnings Recap

Alcon's third-quarter 2025 results demonstrate solid progress, highlighted by strong growth in surgical equipment and contact lenses, while continuing to innovate in ocular health solutions.

Key Takeaways

• Surgical equipment sales exhibit robust momentum, driven by successful Unity VCS and upcoming Unity CS launches, enhancing efficiency in cataract procedures.
• PanOptix Pro is stabilizing market share in the U.S. Trifocal IOL category, with significant advancement in optical design leading to improved patient outcomes.
• Contact lens segment shows double-digit growth in toric modalities, expanding access for astigmatic patients and capturing a significant market opportunity.
• The Systane artificial tears brand continues to gain traction, aided by the successful launch of preservative-free formulations and Tryptyr for dry eye treatment, enhancing patient convenience and experience.
• Alcon's commitment to innovation is underscored by strong performance at major ophthalmic conferences, supporting its competitive positioning in the eye care market.